Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024
Inotiv (Nasdaq: NOTV), a contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2024 fourth quarter and full year financial results announcement for Tuesday, December 3, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Investors can participate via phone (1-800-267-6316 Domestic, 1-203-518-9783 International) or access the webcast through the company's investor relations website.
Inotiv (Nasdaq: NOTV), un'organizzazione di ricerca a contratto focalizzata sui servizi di scoperta di farmaci non clinici e analitici, ha programmato l'annuncio dei risultati finanziari per il quarto trimestre e l'intero anno fiscale 2024 per martedì 3 dicembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 16:30 ora orientale lo stesso giorno per discutere dei risultati. Gli investitori possono partecipare telefonicamente (1-800-267-6316 Domestico, 1-203-518-9783 Internazionale) o accedere alla trasmissione video attraverso il sito web delle relazioni con gli investitori dell'azienda.
Inotiv (Nasdaq: NOTV), una organización de investigación por contrato centrada en los servicios de descubrimiento de fármacos no clínicos y analíticos, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año fiscal 2024 para el martes 3 de diciembre de 2024, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica a las 4:30 p.m. hora del Este el mismo día para discutir los resultados. Los inversores pueden participar por teléfono (1-800-267-6316 Nacional, 1-203-518-9783 Internacional) o acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de la empresa.
이노티브 (Nasdaq: NOTV)는 비임상 및 분석 약물 발견 서비스에 중점을 둔 계약 연구 조직으로, 2024 회계연도 4분기 및 연간 재무 결과 발표를 2024년 12월 3일 화요일 시장 폐장 후에 예정하고 있습니다. 회사는 같은 날 동부 시간으로 오후 4시 30분에 결과를 논의하기 위해 컨퍼런스 콜을 개최할 것입니다. 투자자들은 전화 (1-800-267-6316 국내, 1-203-518-9783 국제)로 참여하거나 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있습니다.
Inotiv (Nasdaq: NOTV), une organisation de recherche contractuelle axée sur les services de découverte de médicaments non cliniques et analytiques, a prévu l'annonce de ses résultats financiers pour le quatrième trimestre et l'ensemble de l'année fiscale 2024 pour mardi 3 décembre 2024, après la fermeture du marché. L'entreprise tiendra une conférence téléphonique à 16h30, heure de l'Est, le même jour pour discuter des résultats. Les investisseurs peuvent participer par téléphone (1-800-267-6316 national, 1-203-518-9783 international) ou accéder à la diffusion en direct via le site Web des relations avec les investisseurs de l'entreprise.
Inotiv (Nasdaq: NOTV), eine Forschungsorganisation im Auftrag, die sich auf nichtklinische und analytische Arzneimittelentdeckungsdienste konzentriert, hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Geschäftsjahr 2024 auf Dienstag, den 3. Dezember 2024, nach Börsenschluss angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz veranstalten, um die Ergebnisse zu besprechen. Investoren können telefonisch teilnehmen (1-800-267-6316 Inlands, 1-203-518-9783 International) oder über die Investor-Relations-Website des Unternehmens auf die Webcast zugreifen.
- None.
- None.
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market.
The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing:
- 1-800-267-6316 (Domestic)
- 1-203-518-9783 (International)
- “INOTIV” (Conference ID)
The live conference call webcast will be accessible in the Investors section of the Company’s web site via the following link:
https://ir.inotiv.com/overview/default.aspx
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://ir.inotiv.com/events-and-presentations/default.aspx.
About the Company
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the impact of recent events related to non-human primate matters on the Company’s business, operations, results, financial condition, cash flows, and assets, the Company’s ability to service its outstanding indebtedness and comply with covenants under its credit agreement, compliance with the Resolution and Plea Agreements with the DOJ and the expected impacts on the Company related to the compliance plan, compliance monitor, and the expected financial commitments, changes in the market and demand for the Company’s products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, claims and litigation against or involving the Company, its business and/or its industry, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations |
| Inotiv, Inc. | LifeSci Advisors |
| Beth A. Taylor, Chief Financial Officer | Steven Halper |
| (765) 497-8381 | 646-676-6455 |
| mailto:beth.taylor@inotiv.com | shalper@lifesciadvisors.com |
FAQ
When will Inotiv (NOTV) release its Q4 and full year 2024 earnings?
How can I listen to Inotiv's (NOTV) Q4 2024 earnings call?
What is the conference ID for Inotiv's (NOTV) Q4 2024 earnings call?
